Taxol based chemotherapy in the treatment of advanced gastric cancer.
- Author:
Yuan LI
1
;
Xiao-qin WU
;
Hui-juan CUI
;
Huang-ying TAN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Alopecia; chemically induced; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cisplatin; administration & dosage; Drug Administration Schedule; Epirubicin; administration & dosage; Female; Fluorouracil; administration & dosage; Humans; Lymph Nodes; pathology; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; administration & dosage; adverse effects; Quality of Life; Remission Induction; Stomach Neoplasms; drug therapy; pathology
- From: Chinese Journal of Oncology 2004;26(9):562-564
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and toxicity of taxol-based chemotherapy in the treatment of advanced gastric cancer (AGC).
METHODSTwenty-nine patients with AGC treated with taxol-based protocols: taxol plus 5-fluouracil 17 patients, taxol plus cisplatin 10 patients, taxol plus epirubicin 2 patients.
RESULTSTwenty-six patients were evaluated for clinical response. There was no complete response, PR 10 (34.5%), SD 12 (41.4%), PD 4 (13.8%). The total response rate was 34.5%. The clinical beneficial response rate was 72.4% (21/29). Median time to progression (mTTP) was 5.8 months and median overall survival time was 9.3 months. The main side effects were: suppression of bone marrow in 26 patients (89.7%), alopecia in 25 (86.2%), myodynia and arthrodynia in 23 (79.3%). There was no death during the treatment.
CONCLUSIONTaxol-based chemotherapy is an effective and well tolerated regimen in the treatment of AUC, which can relieve suffering and improve quality of life of the patients. It can be used as the second-line therapy for relapsed advanced gastric cancer.
